그레이브스병에서 방사성요오드 치료의 최신지견

키워드

참고문헌 (44)

1. 서기현, "건강보험심사평가원 자료로 분석한 우리나라 갑상선기능항진증의 발생률", 유병률 조사와 치료법 선호도의 분석, 2013, pp.6(1), 56~63[DOI]
2. Burch HB, "A 2011 survey of clinical practice patterns in the management of Graves' disease", J Clin Endocrinol Metab, 97(12), pp.4549~4558 (2012)
3. Bartalena L, "A 2013European survey of clinical practice patterns in the management of Graves' disease", Clin Endocrinol (Oxf), 84(1), pp.115~120 (2016)
4. Vaidya B, "Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists", Clin Endocrinol (Oxf), 68(5), pp.814~820 (2008)
5. Walsh JP, "Management of Graves' disease in Australia", Aust N Z J Med, 30(5), pp.559~566 (2000)
6. Bonnema SJ, "Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome", Endocr Rev, 33(6), pp.920~980 (2012)
7. 이가희, "갑상선기능항진증의 진단 및 치료- 대한갑상선학회 합의안", International Journal of Thyroidology, 6(1), pp.1~11 (2013), 대한갑상선학회
8. Kahaly GJ, "2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism", Eur Thyroid J, 7(4), pp.167~186 (2018)
9. Franklyn JA, "The management of hyperthyroidism", N Engl J Med, 330(24), pp.1731~1738 (1994)
10. Ross DS, "2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis", Thyroid, 26(10), pp.1343~1421 (2016)
11. Abraham P, "Current and emerging treatment options for Graves' hyperthyroidism", Ther Clin Risk Manag, 6, pp.29~40 (2010)
12. Peters H, "Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study", Eur J Clin Invest, 25(3), pp.186~193 (1995)
13. Jarløv AE, "Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?", Clin Endocrinol (Oxf), 43(3), pp.325~329 (1995)
14. Leslie WD, "A randomized comparison of radioiodine doses in Graves' hyperthyroidism", J Clin Endocrinol Metab, 88(3), pp.978~983 (2003)
15. Sapienza MT, "Clinical and dosimetric variables related to outcome after treatment of Graves' disease with 550and 1110 MBq of 131I: results of a prospective randomized trial", Clin Nucl Med, 40(9), pp.715~719 (2015)
16. Alexander EK, "High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease", J Clin Endocrinol Metab, 87(3), pp.1073~1077 (2002)
17. Wang J, "Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials", Br J Radiol, 89(1064), pp.20160418~ (2016)
18. Boelaert K, "Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine", J Clin Endocrinol Metab, 98(5), pp.1869~1882 (2013)
19. Brandt F, "Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study", Thyroid, 23(4), pp.408~413 (2013)
20. Giesecke P, "Increased cardiovascular mortality and morbidity in patients treated for toxic nodular goiter compared to Graves'disease and nontoxic goiter", Thyroid, 27(7), pp.878~885 (2017)
21. Metso S, "Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism", J Clin Endocrinol Metab, 92(6), pp.2190~2196 (2007)
22. Nyirenda MJ, "Thyroid disease and increased cardiovascular risk", Thyroid, 15(7), pp.718~724 (2005)
23. Franklyn JA, "Thyroid function and mortality in patients treated for hyperthyroidism", JAMA, 294(1), pp.71~80 (2005)
24. Franklyn JA, "Mortality after the treatment of hyperthyroidism with radioactive iodine", N Engl J Med, 338(11), pp.712~718 (1998)
25. Goldman MB, "Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women", Am J Epidemiol, 127(5), pp.969~980 (1988)
26. Okosieme OE, "Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study", Lancet Diabetes Endocrinol, 7(4), pp.278~287 (2019)
27. Ljunggren JG, "Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study", Thyroid, 8(8), pp.653~659 (1998)
28. Abraham-Nordling M, "Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery", Thyroid, 15(11), pp.1279~1286 (2005)
29. Cramon P, "Quality-of-life impairments persist six months after treatment of Graves' hyperthyroidism and toxic nodular goiter: a prospective cohort study", Thyroid, 26(8), pp.1010~1018 (2016)
30. Bove KB, "Anxiety and depression are more prevalent in patients with graves' disease than in patients with nodular goitre", Eur Thyroid J, 3(3), pp.173~178 (2014)
31. Elberling TV, "Impaired health-related quality of life in Graves' disease. A prospective study", Eur J Endocrinol, 151(5), pp.549~555 (2004)
32. Torring O, "Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for Graves' hyperthyroidism: a long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey", Thyroid, 29(3), pp.322~331 (2019)
33. Abraham-Nordling M, "Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine", Eur J Endocrinol, 163(4), pp.651~657 (2010)
34. Terwee CB, "Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments", Clin Endocrinol (Oxf), 54(3), pp.391~398 (2001)
35. Yeatts RP, "Quality of life in patients with Graves ophthalmopathy", Trans Am Ophthalmol Soc, 103, pp.368~411 (2005)
36. Wartofsky L, "Therapeutic controversies. Summation, commentary, and overview: concerns over aggravation of Graves' ophthalmopathy by radioactive iodine treatment and the use of retrobulbar radiation therapy", J Clin Endocrinol Metab, 80(2), pp.347~349 (1995)
37. Taieb D, "Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study", Eur J Endocrinol, 174(4), pp.491~502 (2016)
38. Bartalena L, "Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy", N Engl J Med, 338(2), pp.73~78 (1998)
39. Acharya SH, "Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review", Clin Endocrinol (Oxf), 69(6), pp.943~950 (2008)
40. Laurberg P, "TSH-receptor autoimmunity in Graves'disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study", Eur J Endocrinol, 158(1), pp.69~75 (2008)
41. Bartalena L, "Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism", N Engl J Med, 321(20), pp.1349~1352 (1989)
42. Bartalena L, "Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO", Eur J Endocrinol, 158(3), pp.273~285 (2008)
43. Bahn RS, "Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists", Endocr Pract, 17(3), pp.456~520 (2011)
44. Watanabe N, "Radioiodine-associated exacerbation of Graves'orbitopathy in the Japanese population: randomized prospective study", J Clin Endocrinol Metab, 100(7), pp.2700~2708 (2015)

관련 논문AI추천